This Fund Bought $28 Million of a Beaten-Down Immunotherapy Stock Last Quarter. What Should Long-Term Investors Know?fool.comThis biotech develops Nanobody-based therapies targeting chronic inflammatory diseases in dermatology and rheumatology markets.
This $64 Million Biotech Exit Seemingly Missed a 77% One-Day Surge on Gilead Takeover Dealfool.comArcellx develops cell-based immunotherapies for cancer, leveraging proprietary platforms to address high unmet needs in oncology.
Biotech Stock Up Nearly 300% Draws $68.7 Million Bet as Breast Cancer Drug Targets 2027 Launchfool.comOlema Pharmaceuticals develops targeted therapies for women's cancers, with a lead candidate in clinical trials for breast cancer treatment.
This Biotech Stock Up 700% Is Still a Top Holding Despite a $9.3 Million Sale Last Quarterfool.comPraxis Precision Medicines develops clinical-stage therapies for neurological disorders, targeting major unmet needs in CNS therapeutics.
